d-serine levels in Alzheimer's disease: implications for novel biomarker development

Alzheimer’s disease (AD) is a severe neurodegenerative disorder still in search of effective methods of diagnosis. Altered levels of the NMDA receptor co-agonist, d-serine, have been associated with neurological disorders, including schizophrenia and epilepsy. However, whether d-serine levels are deregulated in AD remains elusive. Here, we first measured D-serine levels in post-mortem hippocampal and cortical samples from nondemented subjects (n=8) and AD patients (n=14). We next determined d-serine levels in experimental models of AD, including wild-type rats and mice that received intracerebroventricular injections of amyloid-β oligomers, and APP/PS1 transgenic mice. Finally, we assessed d-serine levels in the cerebrospinal fluid (CSF) of 21 patients with a diagnosis of probable AD, as compared with patients with normal pressure hydrocephalus (n=9), major depression (n=9) and healthy controls (n=10), and results were contrasted with CSF amyloid-β/tau AD biomarkers. d-serine levels were higher in the hippocampus and parietal cortex of AD patients than in control subjects. Levels of both d-serine and serine racemase, the enzyme responsible for d-serine production, were elevated in experimental models of AD. Significantly, d-serine levels were higher in the CSF of probable AD patients than in non-cognitively impaired subject groups. Combining d-serine levels to the amyloid/tau index remarkably increased the sensitivity and specificity of diagnosis of probable AD in our cohort. Our results show that increased brain and CSF d-serine levels are associated with AD. CSF d-serine levels discriminated between nondemented and AD patients in our cohort and might constitute a novel candidate biomarker for early AD diagnosis.

[1]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[2]  Benjamin J. Ainscough,et al.  Phosphorylated Tau-Aβ42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid , 2014, Biological Psychiatry.

[3]  Ronald C. Petersen,et al.  Revision of the criteria for Alzheimer's disease: A symposium , 2011, Alzheimer's & Dementia.

[4]  R. Panizzutti,et al.  Plasma levels of D-serine in Brazilian individuals with schizophrenia , 2012, Schizophrenia Research.

[5]  P. Wood,et al.  Presence of the N‐Methyl‐D‐Aspartate‐Associated Glycine Receptor Agonist, D‐Seine, in Human Temporal Cortex: Comparison of Normal, Parkinson, and Alzheimer Tissues , 1993, Journal of neurochemistry.

[6]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[7]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[8]  Robert Lalonde,et al.  The effects of subchronic d-serine on left-right discrimination learning, social interaction, and exploratory activity in APPswe/PS1 mice. , 2013, European journal of pharmacology.

[9]  R. Panizzutti,et al.  d-serine prevents cognitive deficits induced by acute stress , 2014, Neuropharmacology.

[10]  C. Jack,et al.  Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias , 2014, Alzheimer's Research & Therapy.

[11]  I. Radzishevsky,et al.  D-Serine: physiology and pathology , 2013, Current opinion in clinical nutrition and metabolic care.

[12]  F. Pasquier,et al.  A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles , 2014, Alzheimer's Research & Therapy.

[13]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[14]  F. Pasquier,et al.  Impact of harmonization of collection tubes on Alzheimer's disease diagnosis , 2014, Alzheimer's & Dementia.

[15]  G. Fisher,et al.  Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects , 2005, Amino Acids.

[16]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[17]  Herman Wolosker,et al.  d‐Amino acids in the brain: d‐serine in neurotransmission and neurodegeneration , 2008, The FEBS journal.

[18]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[20]  K. Harada,et al.  The presence of free D‐serine in rat brain , 1992, FEBS letters.

[21]  R. Mrak,et al.  Welcome to the Journal of Neuroinflammation! , 2004, Journal of Neuroinflammation.

[22]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[23]  G. McKhann.  Changing concepts of Alzheimer disease. , 2011, JAMA.

[24]  David Loewenstein,et al.  Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. , 2006, Archives of general psychiatry.

[25]  K. Krnjević,et al.  Translational control of mGluR-dependent long-term depression and object-place learning by eIF2α , 2014, Nature Neuroscience.

[26]  D. Foguel,et al.  Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice , 2012, Molecular Psychiatry.

[27]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[28]  R. Rissman,et al.  Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology , 2004, Neurobiology of Disease.

[29]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[30]  C. Parsons,et al.  Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease , 2013, Neurotoxicity Research.

[31]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[32]  H. Brentani,et al.  Amyloid-β Oligomers Induce Differential Gene Expression in Adult Human Brain Slices* , 2012, The Journal of Biological Chemistry.

[33]  R. Panizzutti,et al.  Astrocyte-induced Synaptogenesis Is Mediated by Transforming Growth Factor β Signaling through Modulation of d-Serine Levels in Cerebral Cortex Neurons* , 2012, The Journal of Biological Chemistry.

[34]  M. Spiegel-Adolf,et al.  Cerebrospinal fluid. , 1965, Progress in neurology and psychiatry.

[35]  H. Merritt,et al.  The cerebrospinal fluid , 1938 .

[36]  S. Snyder,et al.  Serine Racemase Deletion Protects Against Cerebral Ischemia and Excitotoxicity , 2010, The Journal of Neuroscience.

[37]  E. Erdfelder,et al.  Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses , 2009, Behavior research methods.

[38]  D. Bennett,et al.  Depressive symptoms, cognitive decline, and risk of AD in older persons , 2002, Neurology.

[39]  O. Arancio,et al.  Reversal of long-term dendritic spine alterations in Alzheimer disease models , 2009, Proceedings of the National Academy of Sciences.

[40]  R. Panizzutti,et al.  Aβ oligomers induce glutamate release from hippocampal neurons. , 2011, Current Alzheimer research.

[41]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[42]  D. Munoz,et al.  TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. , 2013, Cell metabolism.

[43]  L. Kiemeney,et al.  Analysis of Relative Gene Expression Data Using Real-time Quantita- Tive Pcr and the 2 Preanalytic Error Tracking in a Laboratory Medicine Department: Results of a 1-year Experience , 2006 .

[44]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Laplanche,et al.  Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease , 2013, PloS one.

[46]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[47]  R. Wenthold,et al.  Distribution of Glutamate Receptor Subunit NMDAR1 in the Hippocampus of Normal Elderly and Patients with Alzheimer's Disease , 1999, Experimental Neurology.

[48]  E. Engelhardt,et al.  Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Geriatric Depression: Preliminary Findings from Brazil , 2012, CNS neuroscience & therapeutics.

[49]  J. Renger,et al.  A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid , 2014, The Journal of Neuroscience.

[50]  P. Dodd,et al.  Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease , 2004, Journal of neurochemistry.

[51]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[52]  Shaomin Li,et al.  Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.

[53]  F. Boutros-Toni,et al.  Alzheimer CSF biomarkers in routine clinical setting , 2012, Acta neurologica Scandinavica.

[54]  J. Laplanche,et al.  Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease , 2012, Biological Psychiatry.

[55]  Weiming Xia,et al.  A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. , 2009, Archives of neurology.

[56]  G. Fisher,et al.  Free d-serine concentration in normal and Alzheimer human brain , 1995, Brain Research Bulletin.

[57]  Ana P Wasilewska-Sampaio,et al.  Effects of low-dose d-serine on recognition and working memory in mice , 2011, Psychopharmacology.

[58]  Ricardo Nitrini,et al.  Brain bank of the Brazilian aging brain study group—a milestone reached and more than 1,600 collected brains , 2006, Cell and Tissue Banking.

[59]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[60]  K N Sheth,et al.  Purification of serine racemase: biosynthesis of the neuromodulator D-serine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[61]  W. Klein,et al.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[62]  D. Holtzman,et al.  The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. , 2012, Cold Spring Harbor perspectives in medicine.

[63]  P. Bado,et al.  Protein kinase C activity regulates d‐serine availability in the brain , 2011, Journal of neurochemistry.

[64]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[65]  E. Cavalheiro,et al.  Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid-β Oligomers* , 2010, The Journal of Biological Chemistry.

[66]  M. Ciotti,et al.  Contribution of serine racemase/d‐serine pathway to neuronal apoptosis , 2012, Aging cell.

[67]  P. Livrea,et al.  Soluble β-Amyloid1-40 Induces NMDA-Dependent Degradation of Postsynaptic Density-95 at Glutamatergic Synapses , 2005, The Journal of Neuroscience.

[68]  S. Barger,et al.  Induction of serine racemase expression and D-serine release from microglia by amyloid β-peptide , 2004, Journal of Neuroinflammation.

[69]  H. Bading,et al.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.

[70]  Mary Sano,et al.  Preventing Alzheimer’s Disease , 2008, CNS drugs.

[71]  S. Ferreira,et al.  Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease , 2013, Journal of neurochemistry.

[72]  L. Batehup,et al.  A new strategy. , 1992, Nursing times.

[73]  I. Radzishevsky,et al.  The serine shuttle between glia and neurons: implications for neurotransmission and neurodegeneration. , 2013, Biochemical Society transactions.

[74]  Ricardo Nitrini,et al.  Post-Mortem diagnosis of dementia by informant interview , 2010, Dementia & neuropsychologia.

[75]  S. Lipton,et al.  Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss , 2013, Proceedings of the National Academy of Sciences.

[76]  A. Palmeri,et al.  Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer's Disease Mouse Model , 2009, The Journal of Neuroscience.

[77]  R. Panizzutti,et al.  A new strategy to decrease N-methyl-d-aspartate (NMDA) receptor coactivation: Inhibition of d-serine synthesis by converting serine racemase into an eliminase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  T D Bird,et al.  Neuropathological heterogeneity in Alzheimer’s disease: A study of 80 cases using principal components analysis , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[79]  N. Danbolt.  Glutamate uptake , 2001, Progress in Neurobiology.

[80]  S. Lehmann,et al.  Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy , 2014, Front. Aging Neurosci..

[81]  Serine racemase: an unconventional enzyme for an unconventional transmitter , 2012, Amino Acids.

[82]  W. Klein,et al.  N‐Methyl‐d‐aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid‐β peptide oligomers , 2010, Journal of neurochemistry.

[83]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.